
Lyka Labs will face scrutiny over whether this profit rebound survives beyond one strong quarter.
This is one of the cleaner earnings turnaround stories in the feed and has a clear restructuring angle. It matters to investors watching whether the company can sustain the rebound and simplify its portfolio.
AI reasoning
This is one of the cleaner earnings turnaround stories in the feed and has a clear restructuring angle. It matters to investors watching whether the company can sustain the rebound and simplify its portfolio.
Curated summary
Lyka Labs reported standalone Q1 FY27 revenue of Rs 42.31 crore, up 45.7 percent year on year, while net profit jumped to Rs 2.10 crore from Rs 0.81 crore a year earlier. The company also approved selling its 100 percent stake in Lyka BDR International, a subsidiary that contributed 8 percent of consolidated income in FY26 but had negative net worth. Shares rose modestly after the results.
Supporting evidence
YouTube·Market Scientist🎯 “Suzlon Q1 Results 2026 | Revenue Up 22%, Profit Down 6% | Full Analysis & Outlook”
78 engagements1h ago
YouTube·Mr. DkayWhy REC and PFC Crash Today? REC Share Latest News | PFC Share Latest News, Merger Ratio and Date
2h ago
YouTube·ET Now SwadeshStock Market Updates Live:आज कहां करें इन्वेस्ट | Business & Finance | 10th August 2026 |Market Live
2h ago
Source news
Lyka Labs posts sharp Q1 rebound as profit jumps 159% and revenue rises 46%
The pharma company also approved selling a loss-making subsidiary, signaling a cleaner portfolio ahead.
















